Semaglutide in the 2026 European Society of Cardiology guidelines
Authors:
Michal Vrablík; Martin Šatný
Authors place of work:
Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in the journal:
AtheroRev 2026; 11(2): 91-94
Category:
Doporučené postupy
Summary
The 2026 European Society of Cardiology guidelines on cardiovascular (CV) disease in the context of chronic kidney disease (CKD) and heart failure, respectively, document the role of semaglutide in clinical practice. In selected patients with type 2 diabetes mellitus and albuminuric CKD, subcutaneous semaglutide is recommended to slow the progression of renal impairment and reduce CV risk, regardless of diabetes control. In patients with symptomatic heart failure, a left ventricular ejection fraction of at least 45% and concomitant obesity, the use of semaglutide should be considered not only for weight loss but also to improve functional capacity and quality of life. The article summarizes the significance of previously published studies (SELECT, FLOW, STEP-HFpEF and SOUL) for the prevention of atherosclerotic CV events, kidney protection and the treatment of obesity in heart failure. It distinguishes prognostic from symptomatic outcomes and highlights eligibility criteria, evidence gaps and product-specific regulatory restrictions.
Keywords:
obesity – semaglutide – heart failure – chronic kidney disease – cardiovascular prevention
Zdroje
- Damman K, ter Maaten JM, Mayne KJ et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J 2026; ehag098. Dostupné z DOI: <http://doi:10.1093/eurheartj/ehag098>.
- Køber L, Adamo M, Ruwald AC et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J 2026; ehag100. Dostupné z DOI: <http://doi:10.1093/eurheartj/ehag100>.
- Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023; 389(24): 2221–2232. Dostupné z DOI: <http://doi:10.1056/NEJMoa2307563>.
- McGuire DK, Marx N, Mulvagh SL et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 2025; 392(20): 2001–2012. Dostupné z DOI: <http://doi:10.1056/NEJMoa2501006>.
- Perkovic V, Tuttle KR, Rossing P et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024; 391(2): 109–121. Dostupné z DOI: <http://doi:10.1056/NEJMoa2403347>.
- Colhoun HM, Lingvay I, Brown PM et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med 2024; 30(7): 2058–2066. Dostupné z DOI: <http://doi:10.1038/s41591–024–03015–5>.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023; 389(12): 1069–1084. Dostupné z DOI: <http://doi:10.1056/NEJMoa2306963>.
- Kosiborod MN, Petrie MC, Borlaug BA et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024; 390(15): 1394–1407. Dostupné z DOI: <http://doi:10.1056/NEJMoa2313917>.
- Kosiborod MN, Deanfield J, Pratley R et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024; 404(10456): 949–961. Dostupné z DOI: <http://doi:10.1016/S0140–6736(24)01643-X>.
- European Medicines Agency. Ozempic. Souhrn údajů o přípravku. [cit. 2026–10–05]. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf>.
- European Medicines Agency. Wegovy. Souhrn údajů o přípravku. [cit. 2026–10–05]. Dostupné z WWW: <https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf.>
Štítky
Angiologie Diabetologie Interní lékařství Kardiologie Praktické lékařství pro dospěléČlánek vyšel v časopise
Athero Review
2026 Číslo 2
Nejčtenější v tomto čísle
- Kardiovaskulární prevence v každodenní praxi
- Konsenzus pro léčbu hyperurikemie u osob s vysokým kardiovaskulárním rizikem – aktualizace z roku 2025: stručné shrnutí
- Semaglutid v doporučeních Evropské kardiologické společnosti z roku 2026
- Úroveň kontroly kardiovaskulárních rizikových faktorů u pacientů s diabetem 2. typu a hypertenzí v běžné klinické praxi praktických lékařů: výsledky studie BEAT